A gene therapy based on Nobel prize-winning science has partially restored sight in some blind patients, with a clinical ...
Optogenetics, recognized by the 2026 medicine Nobel, makes cells respond to light, including eye cells that normally relay ...
The underlying field was recognized this week when the 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth, MD ...
Optogenetic therapy, based on Nobel prize-winning science, involves turning nerve cells on and off using light ...
Andelyn Biosciences ("Andelyn"), a leading US-based patient-focused cell and gene therapy Contract Development and ...
Pharmaceutical Technology on MSN
Scientists claim Nobel Prize for approach behind light-activated gene therapy
The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, while pharma ...
Ultragenyx Pharmaceutical (RARE) is back in focus after the European Medicines Agency validated its Marketing Authorisation ...
The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as ...
Record global approvals, CRISPR breakthroughs, and expanding clinical and commercial activity are accelerating demand for cell and gene therapy tools and reagents.Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE ...
Zacks Investment Research on MSN
Ultragenyx's gene therapy for Sanfilippo syndrome wins EMA validation
Ultragenyx Pharmaceutical RARE announced that the European Medicines Agency (EMA) has validated its Marketing Authorization ...
Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results